Background Advances in molecular biology and genetics have contributed to breakthrough
treatments directed at specific pathways associated with the development of cancer. Small …

ABSTRACT Introduction By 1 January 2021, the FDA has approved a total of 62 small-
molecule kinase inhibitors (SMKIs). The increasing clinical use of small-molecule kinase …

In recent years, targeted agents have rapidly evolved as effective tools in the clinical
management of a broad range of malignant diseases. These agents disrupt molecular …

Over the last several decades, many new drugs that target molecular pathways in
carcinogenesis and the inflammatory immune system have been developed, resulting in …

The last decade has spawned an exciting new era of oncotherapy in dermatology, including
the development of targeted therapies for metastatic melanoma and basal cell carcinoma …

Contrary to what might have been expected, the effects of targeted therapies are not limited
to the cancer cells and are unfortunately associated with many and numerous adverse …

Background Dermatologic toxicities (DT) to targeted cancer therapy may present as
inflammatory dermatoses, keratoses, and as benign and malignant squamous proliferations …

The world of oncology treatment is rapidly changing, and with the investigation into and
utilization of molecular signaling pathways for cancer treatment, many new targeted small …

A new revolution in cancer therapy has arrived with the development of agents targeting
cancer-related protein kinases, critical regulators of malignant behavior. These drugs are …

Background Currently, molecularly targeted drugs are part of the therapeutic arsenal for the
treatment of many neoplasms and are responsible for improvements in the quality of life and …